<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620802</url>
  </required_header>
  <id_info>
    <org_study_id>CG106</org_study_id>
    <nct_id>NCT00620802</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics of CGT 2168 Compared With Plavix®</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Multiple-Dose, Two-Way Crossover Study of the Pharmacodynamics of CGT 2168 Compared With Plavix®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cogentus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cogentus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CG106 is a Phase I open-label, randomized, multiple-dose, two-way crossover study to&#xD;
      characterize the pharmacodynamics and pharmacokinetics of the investigational fixed-dose&#xD;
      combination product CGT 2168 (clopidogrel, 75 mg and omeprazole, 20 mg) relative to Plavix®&#xD;
      (clopidogrel, 75 mg).&#xD;
&#xD;
      Healthy volunteer subjects will undergo two dosing periods. In each 7-day dosing period,&#xD;
      subjects will receive oral doses of study drug consisting of open-label CGT 2168 or Plavix®&#xD;
      in the order determined by the randomization schedule. Each period of dose administration&#xD;
      will be separated by a two-week washout period. Study exit will occur 1 week after Dosing&#xD;
      Period 2. The expected total duration of participation is 8 weeks (56 days), including a&#xD;
      screening visit on or within 21 days prior to enrollment.&#xD;
&#xD;
      On the day before Day 1 and Day 7 in each dosing period, subjects will be admitted to the&#xD;
      Phase I unit. Blood samples to determine ADP-induced platelet aggregation will be collected&#xD;
      pre-dose on Day 1 and 2 h after dosing on Day 7. Plasma concentrations of clopidogrel parent&#xD;
      and clopidogrel carboxylic acid metabolite will also be measured pre-dose on Day 1 and&#xD;
      pre-dose and serially after dosing on Day 7.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of this study is inhibition of platelet aggregation (IPA) based on maximum platelet aggregation (MPA) to 5 and 20 µM ADP after 7 days daily dosing with CGT-2168 compared to Plavix®.</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual aggregation, measured 10 min after the addition of 20 and 5 µM ADP, after 7 days daily dosing with CGT 2168 compared to Plavix®.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK measures of clopidogrel (parent drug and carboxylic acid metabolite) with CGT 2168 compared to Plavix®.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plavix (clopidogrel 75 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGT-2168</intervention_name>
    <description>(CGT-2168, one capsule each daily)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plavix</intervention_name>
    <description>(clopidogrel, 75 mg)</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females. Women of childbearing potential must have a negative&#xD;
             pregnancy test prior to enrollment and agree to use two methods of effective barrier&#xD;
             contraception, or a hormonal contraceptive to prevent pregnancy throughout the study.&#xD;
&#xD;
          -  Able to comply with study procedures, which includes returning to the Phase I unit for&#xD;
             all scheduled visits and procedures.&#xD;
&#xD;
          -  Abstinence from tobacco use (including smoking cessation products containing nicotine)&#xD;
             for 90 days prior to study entry, with agreement to abstain from tobacco/nicotine use&#xD;
             throughout the study.&#xD;
&#xD;
          -  Agreement to abstain from alcohol and caffeine ingestion from 72 h before dosing and&#xD;
             throughout each dosing period.&#xD;
&#xD;
          -  Able to give informed consent, and subject has signed and dated a written consent form&#xD;
             approved by the IRB.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to clopidogrel, omeprazole, or related drugs including inactive&#xD;
             ingredients.&#xD;
&#xD;
          -  BMI (body mass index) outside the range of 19-30 kg/m2.&#xD;
&#xD;
          -  At screening, body weight less than 50 kg if male or 45 kg if female.&#xD;
&#xD;
          -  Clinically significant abnormal findings on physical examination, clinical laboratory&#xD;
             tests or ECG at screening.&#xD;
&#xD;
          -  History of hypertension or 5-minute sitting screening BP ≥160/100 mmHg on measurements&#xD;
             repeated twice.&#xD;
&#xD;
          -  History of diabetes mellitus, renal failure, acute or chronic liver disease, including&#xD;
             acute or chronic hepatitis, or cirrhosis.&#xD;
&#xD;
          -  Positive HIV-1 antibody, hepatitis B surface antigen or hepatitis C antibody screening&#xD;
             test.&#xD;
&#xD;
          -  History of any clinically significant medical or psychiatric condition.&#xD;
&#xD;
          -  Difficulty in swallowing medication, or any known or suspected gastrointestinal&#xD;
             abnormality that may affect drug absorption.&#xD;
&#xD;
          -  Participation in a previous clinical trial within 30 days prior to enrollment&#xD;
             (check-in on Day -1 for Visit 2).&#xD;
&#xD;
          -  Blood donation of ≥ 1 pint within 30 days or plasma donation within 14 days prior to&#xD;
             enrollment (check-in on Day -1 for Visit 2).&#xD;
&#xD;
          -  Use of any prescription or over-the-counter medications or ingestion of herbal&#xD;
             drugs/dietary supplements including vitamins and minerals within 14 days prior to&#xD;
             enrollment (check-in on Day -1 for Visit 2). Hormonal contraceptives are allowed.&#xD;
&#xD;
          -  Subject is not willing to refrain from drinking grapefruit juice or eating grapefruit&#xD;
             throughout study participation.&#xD;
&#xD;
          -  Subject is an active illicit drug user or has a history of illicit drug use within the&#xD;
             previous 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Lapuerta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cogentus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Phase I Services</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>August 22, 2008</last_update_submitted>
  <last_update_submitted_qc>August 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Pablo Lapuerta, MD</name_title>
    <organization>Cogentus Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Platelet function testing</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

